GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » e-Therapeutics PLC (OTCPK:ETXPF) » Definitions » Profitability Rank

e-Therapeutics (e-Therapeutics) Profitability Rank : 1 (As of Jul. 2023)


View and export this data going back to 2016. Start your Free Trial

What is e-Therapeutics Profitability Rank?

e-Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

e-Therapeutics's Operating Margin % for the quarter that ended in Jul. 2023 was -4,360.19%. As of today, e-Therapeutics's Piotroski F-Score is 4.


Competitive Comparison of e-Therapeutics's Profitability Rank

For the Biotechnology subindustry, e-Therapeutics's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


e-Therapeutics's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, e-Therapeutics's Profitability Rank distribution charts can be found below:

* The bar in red indicates where e-Therapeutics's Profitability Rank falls into.



e-Therapeutics Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

e-Therapeutics has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

e-Therapeutics's Operating Margin % for the quarter that ended in Jul. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Jul. 2023 ) / Revenue (Q: Jul. 2023 )
=-8.982 / 0.206
=-4,360.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

e-Therapeutics has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


e-Therapeutics Profitability Rank Related Terms

Thank you for viewing the detailed overview of e-Therapeutics's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


e-Therapeutics (e-Therapeutics) Business Description

Traded in Other Exchanges
Address
4 Kingdom Street, Paddington, London, GBR, W2 6BD
e-Therapeutics PLC is a drug discovery company. Its ambition is to transform the drug discovery process, leveraging its computational network biology platform (drug discovery) to find novel targets to address mechanisms underpinning complex disease. l company activities are carried out in the UK.

e-Therapeutics (e-Therapeutics) Headlines

No Headlines